Autonomic nervous system and risk factors for vascular disease. Effects of autonomic unbalance in schizophrenia and Parkinson's disease

Neurological Sciences

Volumn 29, Issue 1, 2008, Pages 15-21

  Scigliano, Giulio ^a   Ronchetti, Gabriele ^b   Girotti, Floriano ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Antipsychotic; Cholesterol; Diabetes; Levodopa; Parkinson; Schizophrenia

Indexed keywords

ACETYLCHOLINE; ADRENALIN; CATECHOLAMINE; CLOZAPINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; GLUCOSE; NEUROHORMONE; NEUROLEPTIC AGENT; OLANZAPINE;

ADRENERGIC SYSTEM; ARTERIAL PRESSURE; AUTONOMIC NERVOUS SYSTEM; CARDIOVASCULAR SYSTEM; CHOLINERGIC SYSTEM; CIGARETTE SMOKING; CORONARY ARTERY BLOOD FLOW; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEART CONTRACTION; HORMONE ACTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RELEASE; LIPID METABOLISM; LIPOLYSIS; NEUROTRANSMISSION; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PARKINSON DISEASE; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; THERMOGENESIS; VASCULAR DISEASE; WEIGHT GAIN; AUTONOMIC NEUROPATHY; PHYSIOLOGY;

AUTONOMIC NERVOUS SYSTEM; AUTONOMIC NERVOUS SYSTEM DISEASES; HUMANS; PARKINSON DISEASE; RISK FACTORS; SCHIZOPHRENIA; VASCULAR DISEASES;

EID: 44449149422     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-008-0853-1     Document Type: Review

References (76)

1. Goodman LS, Gillman A (2007) The pharmacological basis of therapeutics. 11th Edn. McGraw-Hill Press, New York
2. B. Ahren 2000 Autonomic regulation of islet hormone secretion- implications for health and disease Diabetologia 43 393 410 10819232 10.1007/s001250051322 1:CAS:528:DC%2BD3cXit12hsLk%3D
3. B. Ahren J.J. Holst 2001 The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and non-cholinergic mechanisms and is important for postprandial glycemia Diabetes 50 1030 1038 11334405 10.2337/diabetes.50.5.1030 1:CAS:528:DC%2BD3MXkvFSguro%3D
4. N. Yamaguchi 1992 Sympathoadrenal system in neuroendocrine control of glucose: mechanisms involved in the liver, pancreas, and adrenal gland under hemorrhagic and hypoglycemic stress Can J Physiol Pharmacol 70 167 206 1521177 1:CAS:528:DyaK38XitFWqu7g%3D
5. W.W. Lautt C. Wong 1978 Hepatic glucose balance in response to direct stimulation of sympathetic nerves in the intact liver of cats Can J Physiol Pharmacol 56 1022 1028 743618 1:CAS:528:DyaE1MXhtlGltbc%3D
6. S.E. Fabris A. Thorburn A. Litchfield J. Proietto 1996 Effect of parasympathetic denervation of liver and pancreas on glucose kinetics in man Metabolism 45 987 991 8769357 10.1016/S0026-0495(96)90268-1 1:CAS:528: DyaK28XlsVSjtLw%3D (Pubitemid 26282552)
7. N. Paquot P. Schneiter E. Jequier L. Tappy 1995 Effects of glucocorticoids and sympathomimetics agents on basal and insulin-stimulated glucose metabolism Clin Physiol 15 231 240 7621645 1:CAS:528:DyaK2MXmtFGmu7o%3D
8. F. Kreier E. Fliers P.J. Voshol, et al. 2002 Selective parasympathetic innervation of subcutaneous and intra-abdominal fat-functional implications J Clin Invest 110 1243 1250 12417562 1:CAS:528:DC%2BD38XosF2gu70%3D
9. L.M. Scott G.H. Tomkin 1985 Cholesterol metabolism: regulatory effects of the vagus in the normal and diabetic animal Diabetes Res 2 313 317 4075700 1:CAS:528:DyaL28Xos1entw%3D%3D
10. A. Giordano C.K. Song R.R. Bowers, et al. 2006 White adipose tissue lacks significant vagal innervation and immunohistochemical evidence of parasympathetic innervation Am J Physiol Regul Integr Comp Physiol 291 1243 1255
11. P. Palatini D. Longo V. Zaetta, et al. 2006 Evolution of blood pressure and cholesterol in stage 1 hypertension: role of autonomic nervous system activity J Hypertens 24 1375 1381 16794487 1:CAS:528:DC%2BD28XmtVOrsbw%3D 10.1097/01.hjh.0000234118.25401.1c (Pubitemid 43948337)
12. L. O'Donnell D. Owens C. McGee, et al. 1988 Effects of catecholamines on serum lipoproteins of normally fed and cholesterol-fed rabbits Metabolism 37 910 915 3173110 10.1016/0026-0495(88)90145-X 1:CAS:528:DyaL1cXlt1ejsb4%3D (Pubitemid 18248796)
13. N.M. O'Meara R.A. Devery D. Owens, et al. 1992 Alterations in cellular cholesterol metabolism following administration of 6-hydroxydopamine to rabbits Br J Pharmacol 105 495 499 1559138 1:CAS:528:DyaK38Xhs1Krtrg%3D
14. R. George T. Ramasarma 1977 Nature of the stimulation of biogenesis of cholesterol in the liver by noradrenaline Biochem J 162 493 9 68775 1:CAS:528:DyaE2sXkvFKntbc%3D
15. J. Gans 1966 Epinephrine and cholesterol metabolism in the dog J Pharmacol Exp Therapy 151 151 157 1:CAS:528:DyaF28XjslCltw%3D%3D
16. G. Mancia G. Grassi C. Giannattasio G. Seravalle 1999 Sympathetic activation in the pathogenesis of hypertension and progression of organ damage Hypertension 34 724 728 10523349 1:STN:280:DyaK1Mvlt1ygsQ%3D%3D
17. B. Egan R. Panis A. Hinderliter, et al. 1987 Mechanism of increased alpha adrenergic vasoconstriction in human essential hypertension J Clin Invest 80 812 817 3040806 10.1172/JCI113138 1:STN:280:DyaL2szgvVyhsg%3D%3D
18. S. Julius A. Mejia K. Jones, et al. 1990 "White coat" versus "sustained" borderline hypertension in Tecumseh, Michigan Hypertension 16 617 623 2246029 1:STN:280:DyaK3M%2FmtVagtg%3D%3D
19. Julius S, Egan B (1986) Hemodynamics of hypertension. In Zanchetti A, Tarazzi RC (eds) Handbook of hypertension. Vol 7: Pathophysiology of hypertension-cardiovascular aspects. Amsterdam, Elsevier pp. 153-178
20. S. Julius S. Majahalme 2000 The changing face of sympathetic overactivity in hypertension Ann Med 32 365 370 10949068 10.3109/07853890008995939 1:STN:280:DC%2BD3M%2FktlOntg%3D%3D
21. D.T. Watts 1960 The effect of nicotine and smoking on the secretion of epinephrine Ann NY Acad Sci 90 74 80 13783473 10.1111/j.1749-6632.1960.tb32619.x 1:CAS:528:DyaF3sXktFWnsbY%3D
22. A. Kershbaum R. Khorsandian R.F. Caplan, et al. 1963 The role of catecholamines in the free fatty acid response to cigarette smoking Circulation 28 52 57 14032101 1:CAS:528:DyaF3sXkslWgsb0%3D
23. J.D. Billimoria H. Pozner B. Metselaar F.W. Best D.C. James 1975 Effects of cigarette smoking on lipids, lipoproteins, blood coagulation, fibrinolysis, and cellular components of human blood Arteriosclerosis 21 61 76 10.1016/0021-9150(75)90094-5 1:CAS:528:DyaE2MXktVWqtb0%3D
24. J.E. Muscat R.E. Harris N.J. Haley E.L. Wynder 1991 Cigarette smoking and plasma cholesterol Am Heart J 121 141 147 1985356 10.1016/0002-8703(91)90967-M 1:CAS:528:DyaK3MXkt1Chsr8%3D
25. C.D. Jolma R.A. Samson S.E. Klewer, et al. 2002 Acute cardiac effects of nicotine in healthy young adults Echocardiography 19 443 448 12356338 10.1046/j.1540-8175.2002.00443.x
26. L.I. Goldberg J.D. Kohli 1979 Peripheral pre-and postsynaptic dopamine receptors: are they different from dopamine receptors in the central nervous system? Commun Psychopharmacol 3 447 456 546591 1:CAS:528:DyaL3cXitFagsbk%3D
27. M. Mannelli R.G. Gheri C. Selli, et al. 1982 A study on human adrenal secretion. Measurement of epinephrine, norepinephrine, dopamine and cortisol in peripheral and adrenal venous blood under surgical stress J Endocrinol Invest 5 91 95 7096922 1:STN:280:DyaL383ktVCgug%3D%3D
28. D.S. Goldstein E. Mezey T. Yamamoto, et al. 1995 Is there a third peripheral catecholaminergic system? Endogenous dopamine as an autocrine/paracrine substance derived from plasma dopa and inactivated by conjugation Hypertens Res 18 [Suppl1] S93 S9 8529081 10.1291/hypres.18. SupplementI-S93 1:CAS:528:DyaK2MXnsFaksrg%3D
29. C. Missale S.R. Nash S.W. Robinson M. Jaber M.G. Caron 1988 Dopamine receptors: from structure to function Physiol Rev 78 189 225
30. M.B. Murphy 2000 Dopamine: a role in the pathogenesis and treatment of hypertension J Hum Hypertens 14 47 50 10.1038/sj.jhh.1000987 1:STN:280:DC%2BD38vnvFamtg%3D%3D
31. S.Z. Langer 1981 Presynaptic regulation of the release of catecholamines Pharmacol Rev 32 337 358
32. J.B. Roussak P. Carey H. Harry 1984 Cardiac arrest after treatment with intravenous domperidone BMJ 289 1579 6439325 1:STN:280:DyaL2M%2FntlCqsw%3D%3D
33. H. Leblanc G.C. Lachelin S. Abu-Fadil S.S. Yen 1977 The effect of dopamine infusion on insulin and glucagon secretion in man J Clin Endocrinol Metab 44 196 198 833258 1:CAS:528:DyaE2sXhtVWgtrg%3D 10.1210/jcem-44-1-196
34. M.R. Lee 1993 Dopamine and the kidney: ten years on [editorial] Clin Sci 84 357 375 8482041 1:CAS:528:DyaK3sXkvVKisLk%3D
35. D. Worth J. Harvey J. Brown M. Lee 1988 The effects of intravenous L-dopa on plasma renin activity, renal function, and blood pressure in man Eur J Clin Pharmacol 35 137 141 3056728 10.1007/BF00609242 1:CAS:528:DyaL1cXls1Cisb8%3D (Pubitemid 18223123)
36. J.R. Sowers G. Berg V.S. Martin D.M. Mayes 1982 Dopaminergic modulation of aldosterone secretion in the rhesus monkey: evidence that dopamine affects the late pathway of aldosterone biosynthesis by inhibiting the conversion of corticosterone to 18-hydroxycorticosterone Endocrinology 110 1173 1177 7060520 1:CAS:528:DyaL38XhslCltb4%3D
37. E. Jungmann M. Wachtler U. Schwedes, et al. 1983 The effect of metoclopramide and haloperidol on plasma renin activity and aldosterone levels in rats Res Exp Med (Berl) 183 133 138 10.1007/BF01851779 1:CAS:528: DyaL2cXivFGlsQ%3D%3D
38. H. Pijl S. Ohashi M. Matsuda, et al. 2000 Bromocriptine: a novel approach to the treatment of type 2 diabetes Diabetes Care 23 1154 1161 10937514 10.2337/diacare.23.8.1154 1:CAS:528:DC%2BD3cXnvV2js7Y%3D
39. V. Kamath C.N. Jones J.C. Yip, et al. 1997 Effects of a quick release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese non diabetic hyperinsulinemic women Diabetes Care 20 1697 1701 9353611 10.2337/diacare.20.11. 1697 1:STN:280:DyaK1c%2FhsFShug%3D%3D
40. D.S. Goldstein C.S. Holmes R. Dendi, et al. 2002 Orthostatic hypotension from sympathetic denervation in Parkinson's disease Neurology 58 1247 1255 11971094 1:STN:280:DC%2BD383jtF2mtg%3D%3D (Pubitemid 34411870)
41. W. Coryell D. Tsuang 1992 Hypothalamic-pituitary-adrenal axis hyperactivity and psychosis: recovery during an 8 year follow-up Am J Psychiatry 149 1033 1039 1636802 1:STN:280:DyaK38zktlyquw%3D%3D
42. C. Enger L. Weatherby R.F. Reynolds, et al. 2004 Serious cardiovascular events and mortality among patients with schizophrenia J Nerv Ment Dis 192 19 27 14718772 10.1097/01.nmd.0000105996.62105.07 (Pubitemid 38101693)
43. E. Redlich 1903 Frage der beziehungen zwischen diabetes mellitus und Psychosen Wien Med Wochenschrift 53 1041 1046
44. M.C. Ryan P. Collins J.H. Thakore 2003 Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia Am J Psychiatry 160 284 289 12562574 10.1176/appi.ajp.160.2.284 (Pubitemid 41110453)
45. J.H. Thakore J.N. Mann I. Vlahos, et al. 2002 Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia Int J Obes Relat Metab Disord 26 137 141 11791159 10.1038/sj.ijo.0801840 1:STN:280:DC%2BD38%2FmsV2quw%3D%3D
46. R.G. McCreadie 2003 Scottish Schizophrenia Lifestyle Group: Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study Br J Psychiatry 183 534 539 14645025 10.1192/bjp.183.6.534 1:STN:280: DC%2BD3srmsFOltQ%3D%3D (Pubitemid 37533200)
47. T.P. Zahn D. Pickar 2005 Autonomic activity in relation to symptom ratings and reaction time in unmedicated patients with schizophrenia Schizophr Res 79 257 270 16006104 10.1016/j.schres.2005.05.025 (Pubitemid 41457266)
48. K.J. Bar A. Letzsch T. Jochum, et al. 2005 Loss of efferent vagal activity in acute schizophrenia J Psychiatr Res 39 519 527 15992561 10.1016/j.jpsychires.2004.12.007 1:STN:280:DC%2BD2Mzktlemug%3D%3D (Pubitemid 40909996)
49. D. Kemali M. Maj M.G. Ariano, et al. 1985 24-hour plasma levels of prolactin, cortisol, growth hormone and catecholamines in schizophrenic patients Neuropsychobiology 14 109 114 3831798 10.1159/000118214 1:STN:280: DyaL287nsFCmtw%3D%3D
50. M.C. Ryan N. Sharifi R. Condren J.H. Thakore 2004 Evidence of basal pituitary-adrenal overactivity in first episode, drug naïve patients with schizophrenia Psychoneuroendocrinology 29 1065 1070 15219658 10.1016/j.psyneuen.2003.08.011 1:CAS:528:DC%2BD2cXlt1Wjsbs%3D (Pubitemid 38833534)
51. E. Shiloah S. Witz Y. Abramovitch, et al. 2003 Effect of acute psychotic stress in nondiabetic subjects on β-cell function and insulin sensitivity Diabetes Care 26 1462 1467 12716805 10.2337/diacare.26.5.1462 (Pubitemid 36929179)
52. T. Chandola E. Brunner M. Marmot 2006 Chronic stress at work and the metabolic syndrome: prospective study BMJ 332 521 525 16428252 10.1136/bmj.38693.435301.80 (Pubitemid 44364369)
53. E.J. Brunner H. Hemingway B.R. Walker, et al. 2002 Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: nested case-control study Circulation 106 2659 2665 12438290 10.1161/01.CIR.0000038364. 26310.BD 1:CAS:528:DC%2BD38XosFCrsrk%3D (Pubitemid 35364919)
54. M. De Hert R. van Winkel D. Van Eyck, et al. 2006 Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study Clin Pract Epidemol Ment Health 2 14 16803620 10.1186/1745-0179-2-14 (Pubitemid 44219613)
55. D.A. Wirshing J.A. Boyd L.R. Meng, et al. 2002 The effects of novel antipsychotics on glucose and lipid levels J Clin Psychiatry 63 856 865 12416594 1:CAS:528:DC%2BD38Xosl2qsLc%3D
56. S. Hagg Y. Lindblom T. Mjorndal R. Adolfsson 2006 High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia Int Clin Psychopharmacol 21 93 98 16421460 10.1097/01.yic.0000188215.84784.17 (Pubitemid 43740316)
57. E. Wooltorton 2004 Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials CMAJ 170 1395 15111472
58. C.U. Correll A.M. Frederickson J.M. Kane P. Manu 2006 Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs J Clin Psychiatry 67 575 583 16669722 1:CAS:528:DC%2BD28XlsVegsbY%3D
59. M. Yumru H.A. Savas E. Kurt, et al. 2007 Atypical antipsychotics related metabolic syndrome in bipolar patients J Affect Disord 98 247 252 16970993 10.1016/j.jad.2006.08.009 1:CAS:528:DC%2BD2sXhtVKhtbc%3D (Pubitemid 46151723)
60. R.S. McIntyre D.A. Mancini V.S. Basile, et al. 2003 Antipsychotic-induced weight gain: bipolar disorder and leptin J Clin Psychopharmacol 23 323 327 12920406 10.1097/01.jcp.0000085403.08426.f4 1:CAS:528:DC%2BD3sXmt1Ohsbg%3D (Pubitemid 36951172)
61. E.A. Koller J.T. Cross Doraiswamy S.N. Malozowski 2003 Pancreatitis associated with atypical antipsychotics: from the Food and Drug Administration's MedWatch surveillance system and published reports Pharmacotherapy 23 1123 1130 14524644 10.1592/phco.23.10.1123.32759 1:CAS:528:DC%2BD3sXnvVKisLc%3D (Pubitemid 37158780)
62. K.J. Zander B. Fischer R. Zimmer M. Ackenheil 1981 Long-term neuroleptic treatment of chronic schizophrenic patients: clinical and biochemical effects of withdrawal Psychopharmacology (Berl) 73 43 47 10.1007/BF00431099 1:STN:280:DyaL3M7pvF2ltA%3D%3D (Pubitemid 11149352)
63. G. Bagdy A. Perenyi E. Frecska, et al. 1985 Decrease in dopamine, its metabolites and noradrenaline in cerebrospinal fluid of schizophrenic patients after withdrawal of long-term neuroleptic treatment Psychopharmacology (Berl) 85 62 64 10.1007/BF00427323 1:STN:280:DyaL2M7ms12htQ%3D%3D (Pubitemid 15159597)
64. J. Staessen R. Fiocchi R. Bouillon, et al. 1985 Differential responses of plasma aldosterone, cortisol and adrenocorticotropin to two dopamine receptor antagonists Methods Find Exp Clin Pharmacol 7 523 527 3001453 1:CAS:528:DyaL28XivVOqug%3D%3D
65. H.A. Nasrallah 2008 Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles Mol Psychiatry 13 27 35 17848919 10.1038/sj.mp.4002066 1:CAS:528:DC%2BD2sXhsVegtLrI (Pubitemid 350275185)
66. K. Wakabayashi H. Takahashi 1997 Neuropathology of autonomic nervous system in Parkinson's disease Eur Neurol 38 [Suppl2] 2 7 9387796 10.1159/000113469
67. R. Volpi P. Caffarra S. Boni, et al. 1997 ACTH/cortisol involvement in the serotoninergic disorder affecting the parkinsonian brain Neuropsychobiology 35 73 78 9097297 10.1159/000119394 1:CAS:528:DyaK2sXitlKltbk%3D
68. B. Bruguerolle N. Simon 2002 Biologic rhythms and Parkinson's disease: a chronopharmacologic approach to considering fluctuations in function Clin Neuropharmacol 25 194 201 12151906 10.1097/00002826-200207000-00002 (Pubitemid 34832759)
69. S.W. Carmichael R.J. Wilson W.S. Brimijoin, et al. 1988 Decreased catecholamines in the adrenal medulla of patients with parkinsonism N Engl J Med 28 254
70. A. Barbeau L. Gillo Joffroy R. Boucher, et al. 1969 Renin-Aldosterone system in Parkinson's disease Science 165 291 292 5787986 10.1126/science.165. 3890.291 1:CAS:528:DyaF1MXksl2jur0%3D
71. A. Pathak J.M. Senard 2006 Blood pressure disorders during Parkinson's disease: epidemiology, pathophysiology and management Expert Rev Neurother 6 1173 1180 16893345 10.1586/14737175.6.8.1173 (Pubitemid 44231975)
72. G. Scigliano M. Musicco P. Soliveri, et al. 2006 Reduced risk factors for vascular disorders in Parkinson's disease patients: a case-control study Stroke 37 1184 1188 16574924 10.1161/01.STR.0000217384.03237.9c (Pubitemid 43731859)
73. Scigliano G, Ronchetti G, Girotti F, Musicco M (2008) Levodopa reduces risk factors for vascular disease in parkinsonian patients. J Neurol (in press)
74. P. Lamberti S. Zoccolella G. Iliceto, et al. 2005 Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients Mov Disord 20 69 72 15390046 10.1002/mds.20261 (Pubitemid 40277507)
75. Y. Ben-Shlomo M.G. Marmont 1995 Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry 58 293 299 7897409 1:STN:280:DyaK2M3gsFWnug%3D%3D 10.1136/jnnp.58.3.293
76. L.K. Struck R.L. Rodnitzky J.K. Dobson 1990 Stroke and its modification in Parkinson's disease Stroke 21 1395 1399 2219202 1:STN:280: DyaK3M%2FitValsg%3D%3D